Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study

Mon, 20 Oct 2025 06:00:00 -0400

-- Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses - confirmed in a representative tumor biopsy - all within two weeks of initial treatment --

Halifax, Nova Scotia--(Newsfile Corp. - October 20, 2025) - Sona Nanotech Inc., (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), is pleased to announce the completion of its first-in-human clinical study treating patients with histologically confirmed, immunotherapy-resistant cutaneous metastatic melanoma using Sona's Targeted Hyperthermia Therapy ("THT"). Ten advanced-stage patients, all of whom were failing to respond to standard immunotherapy treatment, were recruited into this early

Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study

Mon, 20 Oct 2025 06:00:00 -0400

Sona Nanotech To Host Investor Webinar To Discuss Clinical Study

Fri, 17 Oct 2025 16:04:00 -0400

Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20^th at noon EDT to discuss its first-in-human, early feasibility clinical study for its Targeted Hyperthermia Therapy cancer treatment. Ten advanced stage melanoma patients who were failing to respond to standard immunotherapy treatment were recruited into this early feasibility study.

Interested parties can register here: http://bit.ly/3JcFls5. A recording of the webinar will be made available following the webinar in the Investor Information section of the Company's website.

Contact:
David Regan, CEO

Sona Nanotech To Host Investor Webinar To Discuss Clinical Study

Fri, 17 Oct 2025 16:04:00 -0400

Interested parties can register here: http://bit.ly/3JcFls5. A recording of the webinar will be made available following the webinar in the Investor Information section of the Company's website.

Contact:
David Regan, CEO

Sona Provides Update on First-In-Human Clinical Trial

Mon, 25 Aug 2025 09:14:00 -0400

Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, is pleased to provide an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients. The treatment and follow-up assessments of the first cohort of patients have now been completed and treatment on the second cohort of patients has been approved with Sona's Chief Medical Officer arriving in Santiago this past weekend to oversee

Sona Provides Update on First-In-Human Clinical Trial

Mon, 25 Aug 2025 09:14:00 -0400

Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval

Wed, 23 Jul 2025 06:00:00 -0400

Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, has received Nova Scotia Health Research Ethics Board ("REB") approval to conduct its proposed pilot human clinical trial study (the "Pilot Study") of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients. Sona's THT Pilot Study is being planned as a multi-centre clinical trial for 30-40 patients and is subject to, amongst other things, securing medical device Investigational Testing Authorization ("ITA") from

Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval

Wed, 23 Jul 2025 06:00:00 -0400

First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy

Mon, 07 Jul 2025 09:19:00 -0400

Trial is expected to provide key insights on safety, tolerability and immune system response for its THT treatment of late-stage melanoma patients

Halifax, Nova Scotia--(Newsfile Corp. - July 7, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that a first dosing has been achieved in the previously announced early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment.

Dr. Carman Giacomantonio, Sona's CMO, commented, "Our unique therapy aims to modify tumors making them more visible to the

First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy

Mon, 07 Jul 2025 09:19:00 -0400

Trial is expected to provide key insights on safety, tolerability and immune system response for its THT treatment of late-stage melanoma patients
Halifax, Nova Scotia--(Newsfile Corp. - July 7, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that a first dosing has been achieved in the previously announced early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment.
Dr. Carman Giacomantonio, Sona's CMO, commented, "Our unique therapy aims to modify tumors making them more visible to the

Sona Announces Ethics Committee Approval For Melanoma Clinical Trial

Fri, 27 Jun 2025 08:45:00 -0400

Halifax, Nova Scotia--(Newsfile Corp. - June 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment.
Sona CEO David Regan commented, "This ethics committee approval gives us the green light we've been waiting for to begin enrolling patients suffering from late-stage melanoma, for whom no other therapy has worked, to participate in our first-in-human clinical trial.

Sona Announces Ethics Committee Approval For Melanoma Clinical Trial

Fri, 27 Jun 2025 08:45:00 -0400

Halifax, Nova Scotia--(Newsfile Corp. - June 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment.
Sona CEO David Regan commented, "This ethics committee approval gives us the green light we've been waiting for to begin enrolling patients suffering from late-stage melanoma, for whom no other therapy has worked, to participate in our first-in-human clinical trial.

Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy

Mon, 16 Jun 2025 08:23:00 -0400

First Patients Expected to be Enrolled This Month
Halifax, Nova Scotia--(Newsfile Corp. - June 16, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, today announced that it has entered into a clinical trial agreement for an early feasibility study clinical trial of its Targeted Hyperthermia Therapy ("THT"). Sona has engaged Bradford Hill Investigacion Clinica ("Bradford Hill") in Santiago, Chile for a study of Sona's THT treatment for up to ten patients with advanced melanoma.
The study's principal investigator and

Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy

Mon, 16 Jun 2025 08:23:00 -0400

First Patients Expected to be Enrolled This Month
Halifax, Nova Scotia--(Newsfile Corp. - June 16, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, today announced that it has entered into a clinical trial agreement for an early feasibility study clinical trial of its Targeted Hyperthermia Therapy ("THT"). Sona has engaged Bradford Hill Investigacion Clinica ("Bradford Hill") in Santiago, Chile for a study of Sona's THT treatment for up to ten patients with advanced melanoma.
The study's principal investigator and

Sona Successfully Completes FDA-Required Toxicity Study

Tue, 27 May 2025 08:27:00 -0400

Halifax, Nova Scotia--(Newsfile Corp. - May 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold nanorods, conducted by CBSET, Inc.
Donald Hodges, PhD, DSP, DABT, Head of Integrated Toxicology at CBSET, Inc., commented, "This study indicates Sona's gold nanorods were well tolerated, with no signs of acute or systemic toxicity at 100 times the proposed clinical dosage level. The tissue distribution profile was consistent with known nanoparticle pharmacokinetics. These results support the

Sona Successfully Completes FDA-Required Toxicity Study

Tue, 27 May 2025 08:27:00 -0400

Halifax, Nova Scotia--(Newsfile Corp. - May 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold nanorods, conducted by CBSET, Inc.
Donald Hodges, PhD, DSP, DABT, Head of Integrated Toxicology at CBSET, Inc., commented, "This study indicates Sona's gold nanorods were well tolerated, with no signs of acute or systemic toxicity at 100 times the proposed clinical dosage level. The tissue distribution profile was consistent with known nanoparticle pharmacokinetics. These results support the

Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial

Thu, 15 May 2025 09:32:00 -0400

Halifax, Nova Scotia--(Newsfile Corp. - May 15, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the successful completion of bacterial endotoxin testing ("BET") on Sona's uniquely biocompatible gold nanorods using the Limulus Amebocyte Lysate ("LAL") method at a leading global provider of laboratory testing and expert advisory services for MedTech and pharmaceutical companies based in the US.
Sona Nanotech CEO, David Regan, commented, "These great results clear another hurdle for Sona as we move towards our pending first-in-human Early Feasibility study. This study, at a GLP accredited laboratory in the U.S., was

Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial

Thu, 15 May 2025 09:32:00 -0400

Halifax, Nova Scotia--(Newsfile Corp. - May 15, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the successful completion of bacterial endotoxin testing ("BET") on Sona's uniquely biocompatible gold nanorods using the Limulus Amebocyte Lysate ("LAL") method at a leading global provider of laboratory testing and expert advisory services for MedTech and pharmaceutical companies based in the US.
Sona Nanotech CEO, David Regan, commented, "These great results clear another hurdle for Sona as we move towards our pending first-in-human Early Feasibility study. This study, at a GLP accredited laboratory in the U.S., was

BioVaxys and Sona Nanotech Enter Research Collaboration

Wed, 07 May 2025 09:12:00 -0400

Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary

BioVaxys and Sona Nanotech Enter Research Collaboration

Wed, 07 May 2025 09:12:00 -0400

Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary

BioVaxys and Sona Nanotech Enter Research Collaboration

Wed, 07 May 2025 09:12:00 -0400

Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary

BioVaxys and Sona Nanotech Enter Research Collaboration

Wed, 07 May 2025 09:12:00 -0400

Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary

BioVaxys and Sona Nanotech Enter Research Collaboration

Wed, 07 May 2025 08:00:00 -0400

VANCOUVER, BC and HALIFAX, NS, May 7, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The

BioVaxys and Sona Nanotech Enter Research Collaboration

Wed, 07 May 2025 08:00:00 -0400

VANCOUVER, BC and HALIFAX, NS, May 7, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The

BioVaxys and Sona Nanotech Enter Research Collaboration

Wed, 07 May 2025 08:00:00 -0400

VANCOUVER, BC and HALIFAX, NS, May 7, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The

StreetInsider.com News Articles

Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study

Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study

Sona Nanotech To Host Investor Webinar To Discuss Clinical Study

Sona Nanotech To Host Investor Webinar To Discuss Clinical Study

Sona Provides Update on First-In-Human Clinical Trial

Sona Provides Update on First-In-Human Clinical Trial

Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval

Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval

First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy

First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy

Sona Announces Ethics Committee Approval For Melanoma Clinical Trial

Sona Announces Ethics Committee Approval For Melanoma Clinical Trial

Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy

Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy

Sona Successfully Completes FDA-Required Toxicity Study

Sona Successfully Completes FDA-Required Toxicity Study

Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial

Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial

BioVaxys and Sona Nanotech Enter Research Collaboration

BioVaxys and Sona Nanotech Enter Research Collaboration

BioVaxys and Sona Nanotech Enter Research Collaboration

BioVaxys and Sona Nanotech Enter Research Collaboration

BioVaxys and Sona Nanotech Enter Research Collaboration

BioVaxys and Sona Nanotech Enter Research Collaboration

BioVaxys and Sona Nanotech Enter Research Collaboration